KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Treasury Shares (2016 - 2026)

Pacira BioSciences has reported Treasury Shares over the past 7 years, most recently at $227.0 million for Q1 2026.

  • For Q1 2026, Treasury Shares rose 803.68% year-over-year to $227.0 million; the TTM value through Mar 2026 reached $227.0 million, up 803.68%, while the annual FY2025 figure was $176.6 million, 602.86% up from the prior year.
  • Treasury Shares for Q1 2026 was $9.0 million at Pacira BioSciences, up from $6.8 million in the prior quarter.
  • Over five years, Treasury Shares peaked at $9.0 million in Q1 2026 and troughed at $837000.0 in Q2 2024.
  • A 5-year average of $2.4 million and a median of $1.2 million in 2022 define the central range for Treasury Shares.
  • Biggest five-year swings in Treasury Shares: surged 200.61% in 2025 and later soared 803.68% in 2026.
  • Year by year, Treasury Shares stood at $25.1 million in 2024, then skyrocketed by 602.86% to $176.6 million in 2025, then rose by 28.57% to $227.0 million in 2026.
  • Business Quant data shows Treasury Shares for PCRX at $227.0 million in Q1 2026, $176.6 million in Q4 2025, and $125.5 million in Q3 2025.